Ramón García Gómez

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 576 citations · Full text

Medicine, Oncology, Pharmacology +8

Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.

R. Rosell, R. Gervais, A. Vergnenègre et al. · Journal of Clinical Oncology · 2011 · 148 citations

Medicine, Oncology, Pharmacology +16

Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial

Carlos Camps, Bartomeu Massutí, Ángel Martín Jiménez et al. · Annals of Oncology · 2005 · 130 citations

Medicine, Oncology, Pharmacotherapy +11

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

Edurne Arriola, Ramón García Gómez, Pilar Díz et al. · BMC Cancer · 2018 · 15 citations · Full text

Medicine, Oncology, Pharmacology +16

O-253 Early intervention with epoetin alfa maintains hemoglobin (HB) in advanced non-small-cell lung cancer (NSCLC) patients

Robert Milroy, Giorgio V. Scagliotti, Paulus Martin van den Berg et al. · Lung Cancer · 2003 · 12 citations

Medicine, Hematology, Oncology +8